Single-fraction stereotactic radiotherapy for lung malignancies: preliminary results of a mono-institutional experience
Frontiers in Oncology · 19.08.2026 · 16
DOI: 10.3389/fonc.2026.1933254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.08.2026. Verfasst von Francesco Cuccia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital, Palermo, Italy. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The use of stereotactic body radiotherapy for primary and secondary lung lesions is well established. Although being supported by international guidelines, the application of single-fraction treatments is less reported in the literature.
Methods
We report a mono-institutional, retrospective analysis of inoperable patients with small lung lesions—including both primary tumors and oligometastases—treated with single-fraction SBRT (SF-SBRT) via a helical tomotherapy linac. Although analyzed retrospectively, all data were prospectively collected. Acute and late toxicities were graded using CTCAE v5.0, while local control (LC), distant progression-free survival (DPFS), and overall survival (OS) were estimated via Kaplan–Meier and Cox regression models.
Results
From August 2023 a total of 50 lung lesions in 49 patients. median age of 77 years (IQR, 72–80) received SF-SBRT. Thirty patients (61.2%) were male. Seven patients (14.3%) had a pacemaker or implantable cardioverter-defibrillator. Of the 50 treated lesions, 30 (60.0%) were primary NSCLC and 20 (40.0%) were pulmonary metastases, being colorectal cancer the most frequent non-pulmonary primary tumor. Most lesions were located in the right lung (62.0%) and in the upper lobe (64.0%). The median maximum tumour diameter was 1.9 cm (IQR, 1.6–2.4), and median prescription dose, for the entire cohort, was 27 Gy (IQR, 26–28), corresponding to a median BED 10 of 100 Gy (IQR, 93.6–106.4). At a median follow-up of 13.7 months, one local recurrence was observed among the 50 treated lesions (2.0%), distant progression occurred in six of 49 patients (12.2%), while three patients (6.1%) died during follow-up. The estimated 12-month local control, distant progression-free survival and overall survival rates were respectively 100.0%, 89.4% (95% CI, 78.7–100.0%) and 89.5% (95% CI, 78.9–100.0%). No grade 3 or higher adverse events were recorded for both acute and late toxicity patterns.
Conclusions
In elderly patients with a significant burden of comorbidities presenting with isolated lung malignancies, single-fraction SBRT achieved remarkable metabolic responses alongside excellent short-term tolerance and survival. Despite the limitations of a small sample size and few events, these findings support the feasibility and biological effectiveness of single-fraction RT in selected frail subjects, warranting further prospective validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiation Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital, Palermo, Italy.
- Clinical Research, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital, Palermo, Italy.
- Medical Physics, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital, Palermo, Italy.
- Medical Oncology, Azienda Ospedali Riuniti (AOOR) Villa Sofia-Cervello, Palermo, Italy.
- Pneumology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital, Palermo, Italy.
- Medical Oncology, Azienda di Rilievo Nazionale ad Alta Specializzazione (ARNAS) Civico Hospital, Palermo, Italy.
Zitieren
APA
Cuccia, F., Mortellaro, G., Campione, M., Figlia, V., Spera, A., Cespuglio, D., D'Alessandro, S., Napoli, C., Azzarello, F., Verderame, F., Failla, G., Blasi, L., Carruba, G., & Ferrera, G. (2026). Single-fraction stereotactic radiotherapy for lung malignancies: preliminary results of a mono-institutional experience. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1933254
Vancouver
Cuccia F, Mortellaro G, Campione M, Figlia V, Spera A, Cespuglio D, et al. Single-fraction stereotactic radiotherapy for lung malignancies: preliminary results of a mono-institutional experience. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1933254
BibTeX
@article{Cuccia2026,
author = {Cuccia, Francesco and Mortellaro, Gianluca and Campione, Marina and Figlia, Vanessa and Spera, Antonio and Cespuglio, Daniela and D'Alessandro, Salvatore and Napoli, Claudio and Azzarello, Francesco and Verderame, Francesco and Failla, Giuseppe and Blasi, Livio and Carruba, Giuseppe and Ferrera, Giuseppe},
title = {Single-fraction stereotactic radiotherapy for lung malignancies: preliminary results of a mono-institutional experience},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1933254}
}
EUVIMED